JNJ

Johnson & Johnson NYQ · JNJ

$253.04 +3.07 (+1.23%)

Neutral · +0.38σ

+ Compare Open in Sniper

Mkt cap $609.1B

P/E 29.3

Day $251.95 – $255.66

52wk $210.50 – $269.43

Avg vol 8.2M

Beta 0.23

Div yld 2.12%

Next earnings 2026-10-13

Quick read

Plain English

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

JNJ last traded at $253.04, up 1.2% on the day; that's in the upper part of its 52-week range ($210.50–$269.43). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-10-13) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, +0.34 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +0.34 ATR from EMA21 · no notable pattern

· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 6 · tech 6 / 80 · support 0 / 20

below KC1 upper, +0.34 ATR from EMA21 · no notable pattern

· Counter-trend short in strong uptrend

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $107.83 (fair range $104–$157); today's price sits 140% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$107.83

Fair-value range

$103.95 – $157.43

Margin of safety

-140%

Verdict

Overvalued

Accounting quality Weak

✓ Gross margin 68% (pricing power)
✓ Net margin 22%

⚠ Debt exceeds cash
⚠ Quick ratio 0.72 (fragile)
⚠ Receivables growing faster than revenue
⚠ Inventory growing faster than revenue

Price implies ~24% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

JNJ is a $609.1 billion company, priced at 29× last year's earnings, and it moves more calmly than the market (beta 0.2).

Mkt cap $609.1B

P/E ttm 29.3

Fwd P/E 19.7

Beta 0.23

Day range $251.95 – $255.66

52w range $210.50 – $269.43

Avg vol 8.2M

RSI(2) 66.2

ROE —

Net mgn 21.5%

FCF mgn 13.3%

Debt/Eq 0.68

Div yld 2.12%

Sector Healthcare

Industry Drug Manufacturers - General

Next earn 2026-10-13

52-week range · today's price

$210.50$269.43

More on JNJ

Options idea

See more →

CALL $250 2026-08-21

$9.44

PUT $250 2026-08-21

$5.66

Earnings

See more →

Last reported: 2026-07-15
EPS (act / est): 2.90 / 2.85
Surprise: +1.6%
Next report: 2026-10-13

About

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension,…